Dr Reddy’s Sets Out Timelines For Orencia Biosimilar

Updates Offered On Abatacept As Well As Rituximab And Denosumab

 
• By Dave Wallace
  
Dr Reddy’s has seen setbacks on rituximab and denosumab but progress on abatacept (Shutterstock)

More from Biosimilars

More from Products